New asthma pill ADO-5030 enters first human tests
NCT ID NCT07281274
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a single oral dose of ADO-5030 in 36 adults with mild-to-moderate asthma. Researchers will check safety and how the drug affects breathing during a controlled airway challenge. The goal is to gather initial data, not to prove the drug works yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADO-5030 (oral drug)
- What this could lead to
- If successful, this could point toward a new oral treatment to ease asthma symptoms during airway irritation.
- What could go wrong
- This is a very early Phase 1 study with only 36 people, focused on safety and dosing. It may not show meaningful benefit, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Virginia
Charlottesville, Virginia, 22904, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple symptom check replace a grueling exercise test for kids?
- Can ancient cupping ease asthma?
- Could common food additives be friend or foe? a massive study investigates
- Can a new injection help tame asthma? a trial seeks answers
- Could a Two-Day steroid course replace five days for severe asthma in kids?
- Could a simple breathing pattern ease asthma symptoms and improve sleep?